Bimekizumab in Psoriasis: 3-Year Outcomes

• by Kathryn Wighton

• March 12, 2026

Real-life experience of tildrakizumab 200 mg in complex psoriatic patients: a case series

• by Giulia Odorici, Cinzia Buligan, Carolina Fantini, Lucia Mantovani, Giulia Rech, Lidia Sacchelli

• July 14, 2026

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial

• by Richard G. Langley, Lisa Arkin, Loretta Fiorillo, Lawrence F. Eichenfield, Mark Lebwohl, Bruce Strober, Michael Sticherling, Lisa Swanson, Georgios Kokolakis, Siddharth Chaudhari, Cynthia Deignan, Zuoshun Zhang, Amy S. Paller

• May 14, 2026

Psoriasis–AD Switching May Mimic Treatment Failure

Recognizing sustained switches between the two diseases can prevent premature discontinuation of effective biologics and point toward Janus kinase inhibitors, a 148-patient cohort suggests.

• by Andrea Surnit

• June 15, 2026

• 4 min